Background: The clinical significance of the Epstein-Barr virus (EBV) status and p16 expression was unknown in nasopharyngeal carcinoma (NPC). Methods: We retrospectively studied our pathology database for 13 years to determine the prevalence of EBV and p16 expression and their association with prognosis in cases of NPC. We performed immunohistochemistry for the p16 protein and in situ hybridization (ISH) for EBV-encoded small RNAs and human papillomavirus (HPV) DNA. Results: Of the 43 patients with NPC, 27 (63%), 6 (14%), and 10 (23%) cases were EBV positive, EBV negative with keratinization, and EBV negative without keratinization, respectively. No cases were HPV positive by ISH. Among the 21 EBV-positive tumours that were tested for p16, only 2 tumours were p16 positive. The keratinization-positive group included only males, typically >60 years of age (5 of 6) and with T4 tumours (3 of 6). In contrast, the EBV-positive cohort tended to be younger (<60 years, 13 of 27) and have progressive N-stage tumours (N2-3, 14 of 27). The keratinization and EBV-negative cohort included predominantly males (9 of 10) who were likely p16 negative (4 of 10) and smokers (7 of 10). Multivariate analysis confirmed that keratinization was an independent prognostic factor for progression-free survival. Conclusion: In areas, such as Japan, that are nonendemic for both EBV and HPV, the causality of NPC appears to be more heterogeneous.

Keywords:
Nasopharyngeal carcinoma, Keratinization, p16, Prognosis, Japan
1.
Ho HC, Ng MH, Kwan HC, Chau JC: Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976;34:655-660.
2.
Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-428.
3.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
4.
Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI: Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2014;36:511-516.
5.
Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A, et al: HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010;32:562-567.
6.
Zhou Y, Nabeshima K, Koga K, Aoki M, Hayashi H, Hamasaki M, et al: Comparison of Epstein-Barr virus genotypes and clinicohistopathological features of nasopharyngeal carcinoma between Guilin, China and Fukuoka, Japan. Oncol Rep 2008;19:1413-1420.
7.
Saito Y, Ebihara Y, Ushiku T, Omura G, Kobayashi K, Ando M, et al: Negative human papillomavirus status and excessive alcohol consumption are significant risk factors for second primary malignancies in Japanese patients with oropharyngeal carcinoma. Jpn J Clin Oncol 2014;44:564-569.
8.
Cancer Genome Atlas Network: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-582.
9.
El-Naggar AK, Westra WH: p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012;34:459-461.
10.
Sudo M, Chong JM, Sakuma K, Ushiku T, Uozaki H, Nagai H, et al: Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 2004;109:194-199.
11.
Saito Y, Yoshida M, Omura G, Kobayashi K, Fujimoto C, Ando M, et al: Prognostic value of p16 expression irrespective of human papillomavirus status in patients with oropharyngeal carcinoma. Jpn J Clin Oncol 2015;45:828-836.
12.
Odell EW, Jani P, Sherriff M, Ahluwalia SM, Hibbert J, Levison DA, et al: The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. The importance of the pattern of invasion. Cancer 1994;74:789-794.
13.
Cooper T, Biron VL, Adam B, Klimowicz AC, Puttagunta L, Seikaly H: Association of keratinization with 5-year disease-specific survival in oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:250-256.
14.
Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:3755-3762.
15.
Rassouli A, Saliba J, Castano R, Hier M, Zeitouni AG: Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck 2015;37:103-110.
16.
Sun W, Zhang L, Luo M, Luo M, Hu G, Mei Q, et al: Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck DOI: 10.1002/hed.24224.
17.
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al: p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 2014;32:3930-3938.
18.
Dreyer JH, Hauck F, Oliveira-Silva M, Barros MH, Niedobitek G: Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal. Virchows Arch 2013;462:381-389.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.